After metformin in the glucose-lowering treatment plan for patients with T2DM and CKD, both the American Diabetes Association and the Korean Diabetes Association advise clinicians to consider incorporating SGLT2 inhibitors or GLP-1 receptor agonists. Here, SLC5A2 is linked to chronic kidney disease.